Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

Haematologica, Vol 93, Issue 1, 147-148 doi:10.3324/haematol.11771
Copyright © 2008 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Illerhaus, G.
Right arrow Articles by Finke, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Illerhaus, G.
Right arrow Articles by Finke, J.

Malignant Lymphomas

High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system

Gerald Illerhaus1,, Fabian Müller1, Friedrich Feuerhake2, Arnd-Oliver Schäfer3, Christoph Ostertag4, Jürgen Finke1

1 Departments of Haematology and Oncology
2 Neuropathology
3 Radiology
4 Stereotactic Neurosurgery, University Medical Center Freiburg, Freiburg, Germany

Correspondence: Gerald Illerhaus, MD, University Medical Center Freiburg, Dept. of Hematology and Oncology, Hugstetter Str. 55, D-79106 Freiburg, Germany., Phone: international +49.761.2703785. Fax: international +49.761.270.7357. E-mail: gerald.illerhaus{at}uniklinik-freiburg.de

Thirteen patients (age 38–67 years) with primary lymphoma of the central nervous system (CNS) were treated with methotrexate and cytarabine/thiotepa induction-chemotherapy followed by high-dose carmustine/thiotepa and autologous stem-cell transplantation. Radiotherapy was restricted to patients who did not respond completely to chemotherapy. With a median follow up of 25 months, 3-year DFS and OS was 77%.

Key words: PCNSL, high-dose chemotherapy, stem-cell transplantation, whole-brain-radiotherapy, neurotoxicity.




This article has been cited by other articles:


Home page
 The OncologistHome page
M. Sierra del Rio, A. Rousseau, C. Soussain, D. Ricard, and K. Hoang-Xuan
Primary CNS Lymphoma in Immunocompetent Patients
Oncologist, May 1, 2009; 14(5): 526 - 539.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in Neurological DisordersHome page
U. Schlegel
Review: Primary CNS lymphoma
Therapeutic Advances in Neurological Disorders, March 1, 2009; 2(2): 93 - 104.
[Abstract] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2008 by the Ferrata Storti Foundation.